Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.38 |
| ▸ | SPR | P35270 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | HTR3A | P46098 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.30 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29324752 | 0.81 | GSK3B (0.39) | GSK3BSPRPOLBCYP1A2HCRTR1 | |
| SCHEMBL18538049 | 0.81 | ALDH1A1 (0.42) | GSK3BPOLBCYP1A2MAPT | |
| SCHEMBL28619610 | 0.80 | HSD17B10 (0.40) | GSK3BSPRPOLBHCRTR1HCRTR2 | |
| SCHEMBL18538040 | 0.80 | HPGD (0.40) | GSK3BSPRPOLBL3MBTL1HCRTR1 | |
| SCHEMBL16167735 | 0.77 | SPR (0.52) | GSK3BSPRPOLBCYP1A2PDE10A | |
| SCHEMBL19480629 | 0.76 | GSK3B (0.58) | GSK3BSPRPOLBHTR3APDE10A | |
| SCHEMBL19230910 | 0.76 | SPR (0.36) | GSK3BSPRPOLBHTR3APDE10A | |
| SCHEMBL25091051 | 0.75 | HCRTR1 (0.33) | CYP1A2HCRTR1HCRTR2 | |
| SCHEMBL29582154 | 0.72 | PI4KA (0.36) | GSK3BHCRTR1HCRTR2 | |
| SCHEMBL25091063 | 0.72 | HCRTR1 (0.38) | GSK3BCYP1A2L3MBTL1PDE10AHCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | GSK3B 581/4885SPR 3510/4885POLB 492/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | GSK3B 948/4885SPR 4400/4885POLB 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.